Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Dragonfly Therapeutics Partners With AbbVie

Dragonfly Therapeutics and AbbVie forged a multi-target research collaboration to advance new treatment options for autoimmune and oncology indications.

Read More »

Bristol-Myers wins antitrust approval to buy Celgene

Bristol-Myers Squibb Co. and Celgene Corp. won U.S. antitrust approval for their merger on condition that they sell Celgene’s psoriasis drug Otezla.

Read More »

AstraZeneca succeeds in treating lupus in late-stage study

AstraZeneca Plc’s experimental treatment anifrolumab significantly reduced disease activity in patients with the autoimmune disorder lupus in a late-stage study.

Read More »

Mallinckrodt receives SEC subpoena over Acthar gel lawsuit

Mallinckrodt Plc received a subpoena from the U.S. Securities and Exchange Commission for documents related to the drugmaker’s lawsuit against the U.S. Department of Health and Human Services (HHS).

Read More »

FDA Approves Vumerity for Multiple Sclerosis

The U.S. Food and Drug Administration approved Vumerity (diroximel fumarate) – a novel oral fumarate with a distinct chemical structure – for the treatment of relapsing forms of multiple sclerosis.

Read More »

Gilead and Galapagos’ JAK Inhibitor Stumbles in Mid-Stage Lupus Trial

Despite the success Gilead Sciences has experienced with the JAK inhibitor filgotinib in rheumatoid arthritis, the medication failed to hit the mark in mid-stage trials aimed at lupus and Sjogren’s syndrome.

Read More »

Acorda to terminate 25 percent of headcount via restructuring

Acorda Therapeutics will terminate approximately 25 percent of headcount as the company initiates a corporate restructuring.

Read More »

Q3 2019 sales of Lilly diabetes drug Trulicity fall short

Eli Lilly third-quarter 2019 sales missed Wall Street estimates as rebates limited revenue from the drug manufacturer’s top-selling diabetes medicine Trulicity, and shares fell about 4 percent.

Read More »

FDA approves Janssen’s Stelara for ulcerative colitis

The U.S. Food and Drug Administration approved Janssen’s Stelara (ustekinumab) for the treatment of adult patients with moderately to severely active ulcerative colitis.

Read More »

UCB hits the mark in bimekizumab psoriasis study

A little more than a week after announcing plans to acquire Ra Pharmaceutical for $2.1 billion, UCB’s psoriasis drug bimekizumab met all endpoints in the first of three Phase III studies.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom